CCND1 amplification can predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib, although these agents have reported only limited efficacy as monotherapy in tumor types other than breast cancer [37,38]. Here, CCND1 is linked to breast carcinoma.